Cell therapy and brain function in AIHA
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial looks at how cell therapy may affect your brain function and mood if you have autoimmune hemolytic anemia. It aims to help doctors understand the psychological changes that can happen during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with autoimmune hemolytic anemia (AIHA).
- You are planning to receive cell therapy (like CAR T-cell therapy) for your AIHA.
- You are between 18 and 65 years old.
- You are willing to follow the study rules and give your written consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This study tests an experimental cell therapy called YTS109 for people with autoimmune hemolytic anemia (AIHA) or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can help control the anemia and reduce the need for ongoing treatments.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study watches patients getting CAR-T cell therapy to see if it affects brain function, thinking, or memory. It aims to find out how common these effects are and help doctors manage them.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
This study uses brain scans and blood markers to understand how CAR T-cell therapy affects the brain. It may help researchers predict or manage potential side effects.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.